Bausch Health Companies (BHC) Projected to Post Quarterly Earnings on Thursday

Bausch Health Companies (NYSE:BHC) is expected to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of $1.12 per share for the quarter. Bausch Health Companies has set its FY 2025 guidance at EPS.Parties that wish to listen to the company’s conference call can do so using this link.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 650.39%. The company had revenue of $2.56 billion during the quarter, compared to analyst estimates of $2.51 billion. On average, analysts expect Bausch Health Companies to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Bausch Health Companies Trading Down 1.8 %

Shares of NYSE:BHC opened at $7.18 on Tuesday. Bausch Health Companies has a 12-month low of $3.96 and a 12-month high of $11.46. The company has a market capitalization of $2.64 billion, a PE ratio of -59.79, a PEG ratio of 0.38 and a beta of 0.68. The business has a 50 day moving average of $7.34 and a two-hundred day moving average of $7.52.

Analyst Upgrades and Downgrades

BHC has been the subject of a number of analyst reports. Royal Bank of Canada decreased their price target on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a report on Thursday, January 30th. Jefferies Financial Group reissued a “hold” rating and issued a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, Bausch Health Companies has an average rating of “Hold” and a consensus price target of $7.42.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.